Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …

Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

With nearly 10 million deaths, cancer is the leading cause of mortality worldwide. Along with
major key parameters that control cancer treatment management, such as diagnosis …

Cancer stem cells (CSCs) are self-renewing cells that facilitate tumor initiation, promote
metastasis, and enhance cancer therapy resistance. Transcriptomic analyses across many …

Since the introduction of the cancer stem cell (CSC) paradigm, significant advances have
been made in understanding the functional and biological plasticity of these elusive …

An extensive body of literature describes anticancer property of dichloroacetate (DCA), but
its effective clinical administration in cancer therapy is still limited to clinical trials. The …

Cancer-derived extracellular vesicles (EVs) have been detected in the bloodstream and
other biofluids of cancer patients. They carry various tumor-derived molecules such as …

Despite great strides being achieved in improving cancer patients' outcomes through better
therapies and combinatorial treatment, several hurdles still remain due to therapy …

Cancer cell dormancy is a common feature of human tumors and represents a major clinical
barrier to the long-term efficacy of anticancer therapies. Dormant cancer cells, either in …

Chemotherapy typically destroys the tumor mass but rarely eradicates the cancer stem cells
(CSCs) that can drive metastatic recurrence. A key current challenge is finding ways to …